Category: Pharmaceuticals - Page 3

Patent Term Restoration (PTE): How Drug Patents Get Extra Life After FDA Delays

Jan, 13 2026| 9 Comments

Patent Term Restoration (PTE) gives drug makers extra patent life to make up for FDA approval delays. Learn how it works, who qualifies, and why it’s controversial.

Injectable Medication Shortages: Why Hospital Pharmacies Are on the Front Line

Jan, 11 2026| 9 Comments

Hospital pharmacies are facing severe shortages of injectable medications due to complex manufacturing, low profit margins, and global supply chain risks. Patients, especially the elderly and critically ill, are paying the price.

FDA Bioequivalence Standards for NTI Drugs: Special Requirements Explained

Jan, 8 2026| 15 Comments

The FDA enforces stricter bioequivalence standards for narrow therapeutic index (NTI) drugs like warfarin, digoxin, and phenytoin, requiring tighter limits (90-111%) and replicate studies to ensure patient safety. These rules prevent dangerous fluctuations in blood levels that can occur with generics.

Beta-Blockers: How Different Types Interact and Why Drug Choice Matters

Jan, 3 2026| 11 Comments

Not all beta-blockers are the same. Learn how carvedilol, nebivolol, and propranolol differ in action, side effects, and use for heart failure, hypertension, and asthma. Make informed choices with your doctor.

How Fatty Foods Boost Absorption of Lipid-Based Medications

Dec, 31 2025| 12 Comments

Fatty foods enhance absorption of lipid-based medications by triggering natural digestive processes that help dissolve poorly soluble drugs. Learn how these formulations work, which drugs benefit most, and what patients need to know about dosing, cost, and effectiveness.

Combination NTI Drugs and Generic Availability: Coverage and Gaps

Dec, 30 2025| 14 Comments

Combination NTI drugs offer powerful treatment but carry extreme risks when switched to generics. With no approved generic combinations in the U.S., patients face higher costs, more monitoring, and serious safety gaps.

FDA Listing for Biosimilars: How They Are Evaluated and Approved

Dec, 26 2025| 14 Comments

The FDA doesn't rate biosimilars like generics-they undergo a rigorous, science-based approval process to prove they're highly similar to reference biologics with no clinically meaningful differences in safety or effectiveness.

Azoles and Tacrolimus: How Drug Interactions Cause Dangerous Level Spikes and Kidney Damage

Dec, 22 2025| 9 Comments

Azoles like voriconazole can cause dangerous spikes in tacrolimus levels, leading to acute kidney injury in transplant patients. Learn how this common drug interaction works, who's at risk, and how to prevent it.

SSRIs and Anticoagulants: What You Need to Know About the Bleeding Risk

Dec, 17 2025| 13 Comments

Combining SSRIs with anticoagulants increases bleeding risk by 33%, especially in the first 30 days. Learn why this happens, which drugs are riskiest, and what safer alternatives exist.

Crossover Trial Design: How Bioequivalence Studies Are Structured

Dec, 10 2025| 12 Comments

Crossover trial designs are the gold standard for bioequivalence studies, using each participant as their own control to reduce variability and sample size. Learn how AB/BA and replicate designs work, when to use them, and what regulators require.